AstraZeneca Covid-19 vaccine trial would resume shortly

As per the recent update, the British biotech firm AstraZeneca (LON: AZN) would resume its trials for the experimental COVID-19 vaccine next week. On Tuesday, Pharmaceutical giant AstraZeneca suspended the late-stage trials after an illness in a study subject in Britain. The patient was reportedly suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis. The experimental vaccine being developed with the University of Oxford against the novel coronavirus.

Meanwhile, AstraZeneca’s CEO Pascal Soriot said today, “we should know before year-end whether the potential COVID-19 vaccine will protect people”. “Data from the sick and symptomatic volunteer will be sent to an independent safety and health committee and the company will either continue or complete the trials, depending on the outcome” he added.

Earlier AstraZeneca planned to have its vaccine available by the first half of 2021 and was considered one of the most advanced in the world by the World Health Organization (WHO).

AstraZeneca’s vaccine, called AZD1222, uses genetic material from the coronavirus with a modified adenovirus. The company has already agreed to supply close to three billion doses to governments across the globe — more than any other vaccine project.

The shares of AstraZeneca slightly rebounded from the previous session lows. On Wednesday, the stock slipped after the drugmaker said it has paused late-stage trials of its coronavirus vaccine.

--

--

--

A financial investment professional with over 9 years of FX and capital market industry. Chief analyst at Gulf Brokers https://gulfbrokers.com/en/research/blog

Love podcasts or audiobooks? Learn on the go with our new app.

Recommended from Medium

Not Only China/Exclusive — A Pandemic Originating in Fort Detrick, USA

Ways to Support Someone Recovering from COVID-19

Self portrait art from Color Blynd by Noni

The Latest Lethal Lie

Is This Our New Normal?

Coronavirus taught us the importance of life but not of death

Science in the News

Vaccines, overconfidence and 98% cuts

Young Indian Women Are Using Instagram To Tell The World How Bad Things Are

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Syam KP | Gulf Brokers

Syam KP | Gulf Brokers

A financial investment professional with over 9 years of FX and capital market industry. Chief analyst at Gulf Brokers https://gulfbrokers.com/en/research/blog

More from Medium

‘Partygate’ and the Degeneration of British Politics

Dugin: Secrets behind the Kremlin Ideologue

Reflections on the Warrior Archetype in the Age of Neo-Feudalism

Ukraine moves to digitally preserve its national landmarks